Stockscreener 앱 받기
27.19
0.96%
-0.3063
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire
Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat
Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN
Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire
Spyre Therapeutics revises net loss per share calculations - Investing.com
Spyre Therapeutics launches $200 million public offering - Investing.com
Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan
Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat
Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com
SYRE Crosses Below Key Moving Average Level - Nasdaq
Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com
Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com
Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat
Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia
FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com
Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World
Spyre reports promising Phase 1 results for IBD therapy - Investing.com India
Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World
Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan
Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat
Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK
Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com
Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World
Spyre Therapeutics director sells shares worth $10,929 - Investing.com India
Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa
Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat
Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
SPY-003, an extended half-life MAb with twice-a-year projected human maintenance dosing - BioWorld Online
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News
Wedbush’s latest rating for SYRE stock - Knox Daily
SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat
Spyre Therapeutics Advances SPY003 for IBD Treatment - TipRanks
Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK
Spyre Therapeutics advances IBD antibody treatments - Investing.com
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations - PR Newswire
The Manufacturers Life Insurance Company Takes $888,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
1.80%
0.42%
자본화:
|
볼륨(24시간):